Please login to the form below

Not currently logged in
Email:
Password:

Icon boost medical device trial capability with Aptiv acquisition

Deal will also enhance the CRO's position inadaptive trials and in Japan

Dublin-based contract research organisation Icon has acquired Aptiv Solutions for $143.5m, boosts its capabilities to run adapative and medical device trials.  

The deal will also expand Icon's footprint in Japan, allowing it to combine its existing operations in Tokyo and Osaka with Niphix, a full-service oncology-focused CRO owned by Aptiv.  

Dr Nuala Murphy, president of Icon Clinical Research Services, said: “Icon's market-leading innovation is helping our customers to reduce the time and cost of drug development.  

“Aptiv Solutions' adaptive trial capabilities will further differentiate and enhance our services to help our customers identify the most promising drug candidates earlier. Their presence in Japan will also broaden our existing capabilities in this market.”  

Icon's acquisition of Aptiv comes some six weeks after the US-headquartered CRO teamed up with Novartis, Janssen and Lilly to form a consortium to work on adaptive dose finding trials.  

The ADDPLAN DF Consortium partners will collaborate on developing new statistical methodologies for the design of innovative dose-finding clinical trials, with an emphasis on adaptive designs.  

It's an area European regulators are planning to look at in more details soon, when they launch an adaptive licensing pilot.

Article by
Dominic Tyer

2nd April 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Videum Health

Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...

Latest intelligence

David Atkins
A snapshot of Congenica
PME talks to CEO David Atkins...
Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...

Infographics